ACESION PHARMA ApS: Financial statements 2024
CVR: 34083738
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
ACESION PHARMA ApS (CVR 34083738) has filed annual accounts for 2024. In 2024, the company reported a net result of DKK -43,033,000 compared with DKK -42,849,000 the year before. Equity in the 2024 report amounted to DKK 89,642,000. The solvency ratio was 77.2%.
- Profit/Loss
- DKK -43,033,000
- Equity
- DKK 89,642,000
- Total Assets
- DKK 116,146,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | - | -43 mio. | 89.6 mio. | - |
| 2023 | - | - | -42.8 mio. | 130.8 mio. | - |
| 2022 | - | - | -46.8 mio. | 23 mio. | - |
| 2021 | 0 | - | -25.2 mio. | 10.3 mio. | - |
| 2020 | 0 | - | -31.4 mio. | -20 mio. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
ACESION PHARMA ApS has published its annual report for 2023. The net result was DKK -42,849,000.
As of February 28, 2024, Benjamin Bruno Thorner has joined the board of directors of ACESION PHARMA ApS.
About ACESION PHARMA ApS
ACESION PHARMA ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2011. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Anders Gaarsdal Holst. The board consists of Jørgen Søberg Petersen (chair), Benjamin Bruno Thorner, Nik Economopoulos and Timothy Michael Shannon. The company's owners include Novo Holdings A/S, Canaan XII L.P. and Alpha Wave Ventures II, LP. The company has 14 employees (2018). In 2025, the company reported a net result of DKK -59,597,000 compared with DKK -43,033,000 the year before. Equity in the 2025 report amounted to DKK 276,067,000.